8-K: Esperion Reports Mixed Q1 2025: Revenue Declines Due to Prior Milestone, U.S. Product Sales Rise

Esperion Therapeutics reports a 53% decrease in total revenue for Q1 2025, primarily due to the absence of a milestone payment received in Q1 2024, though U.S. product revenue increased by 41%.

Summary

• Esperion Therapeutics announced its Q1 2025 financial results, reporting a total revenue of $65.0 million, a 53% decrease compared to $137.7 million in Q1 2024.
• This decrease is primarily attributed to a one-time milestone payment received from Daiichi Sankyo Europe (DSE) in the prior year's quarter.
• Excluding this milestone, total revenue grew by 63% year-over-year.
• U.S. net product revenue increased by 41% to $34.9 million.
• Collaboration revenue decreased by 73% to $30.1 million, again due to the absence of the milestone payment, but grew 97% excluding the milestone.
• The company's net loss was $40.5 million, compared to a net income of $61.0 million in Q1 2024.
• Basic and diluted net loss per share was $0.21, compared to net income per share of $0.36 and $0.34 in the prior year.
• As of March 31, 2025, cash and cash equivalents totaled $114.6 million, down from $144.8 million at the end of 2024.
• Esperion expects full-year 2025 operating expenses to be in the range of $215 million to $235 million.
• The company surpassed one million retail prescription equivalents for its bempedoic acid products in the U.S.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased due to a prior milestone payment, U.S. product revenue grew, and the company is expanding its pipeline and receiving favorable guideline recommendations. However, the net loss and cash decrease temper the positive aspects.

Positives

• U.S. net product revenue increased by 41% year-over-year.
• DSE's royalty revenue increased 8% sequentially.
• Esperion surpassed one million retail prescription equivalents for its bempedoic acid products in the U.S.
• The company is expanding its development portfolio with a novel program targeting Primary Sclerosing Cholangitis (PSC).
• Bempedoic acid earned Level 1a recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes.
• The company expanded its reimbursement team from five to 15 field specialists, enhancing support for both providers and patients.
• More than 30 plans, including several of the nation's largest insurers, improved formulary positioning across 361 distinct formularies.

Negatives

• Total revenue decreased by 53% year-over-year due to the absence of a milestone payment received in Q1 2024.
• The company reported a net loss of $40.5 million, compared to a net income of $61.0 million in Q1 2024.
• Cash and cash equivalents decreased from $144.8 million at the end of 2024 to $114.6 million as of March 31, 2025.

Risks

• The company's financial performance is heavily reliant on the success of its bempedoic acid products.
• The company faces competition from other lipid-lowering therapies.
• The company's future success depends on its ability to successfully develop and commercialize new products.
• The company's operating expenses are expected to be significant in 2025, which could impact profitability.

Future Outlook

Esperion expects full-year 2025 operating expenses to be in the range of $215 million to $235 million, including approximately $15 million in non-cash expenses related to stock compensation.

Management Comments

• Throughout the first quarter, we continued to make important progress advancing our three pillars for growth: revenue growth, portfolio expansion and pipeline advancement, stated Sheldon Koenig, President and CEO of Esperion.
• We were excited to surpass our one millionth prescription for our bempedoic acid products in the U.S. and, while the overall lipid market was flat in the first quarter of 2025, we are implementing initiatives to drive growth by introducing new marketing around statin intolerance and leveraging recent inclusion in clinical guidelines.
• Importantly, we have increased our field reimbursement specialists three-fold to ensure that physicians can write prescriptions with confidence in its coverage.
• We were especially pleased to share our exciting news regarding pipeline expansion at our recent R&D Day, where we unveiled our promising research supporting lead development candidates, including ESP-1336, for the treatment of Primary Sclerosing Cholangitis (PSC), a market estimated to be greater than $1 billion, added Koenig.

Industry Context

Esperion is operating in the competitive lipid-lowering market, where it faces competition from established statins, as well as newer therapies like PCSK9 inhibitors and other emerging oral treatments; the company is focusing on statin-intolerant patients and leveraging guideline inclusions to drive growth.

Comparison to Industry Standards

• Esperion's focus on non-statin therapies aligns with a growing trend in the cardiovascular space, where alternative LDL-C lowering options are being explored for patients who cannot tolerate statins.
• Companies like Amgen and Regeneron, with their PCSK9 inhibitors (Evolocumab and Alirocumab, respectively), also target LDL-C reduction, but through a different mechanism of action.
• The development of triple combination products with bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin, aiming for LDL-C lowering in excess of 60%, positions Esperion to potentially rival injectable and emerging oral therapies.
• Esperion's expansion into Primary Sclerosing Cholangitis (PSC) mirrors other biopharmaceutical companies diversifying their pipelines to address unmet medical needs in liver and kidney diseases.

Stakeholder Impact

• Shareholders: The mixed financial results may lead to uncertainty among investors.
• Employees: Pipeline expansion and commercial progress could boost employee morale.
• Customers: New marketing initiatives and guideline inclusions could improve patient access to Esperion's products.
• Partners: Continued collaboration with DSE and Otsuka is crucial for international growth.

Next Steps

• Continue implementing marketing initiatives to reach statin intolerant patients.
• Advance development of two triple combination products in the U.S.
• Support Otsuka Pharmaceutical Co., Ltd. for expected approval and National Health Insurance pricing in Japan.
• Support Daiichi Sankyo Europe (DSE) in their continued market penetration.
• Continue review of New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET.
• Advance research and development of lead development candidates for the treatment of PSC.

Key Dates

Keywords

Esperion, Bempedoic Acid, NEXLETOL, NEXLIZET, NILEMDO, NUSTENDI, Lipid Lowering, Cardiovascular Disease, Cholesterol, Financial Results, Q1 2025, Pharmaceuticals